Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
(OP:
LOBEF
)
0.0153
UNCHANGED
Streaming Delayed Price
Updated: 1:15 PM EDT, Apr 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
0.0153
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0153
Today's Range
0.0153 - 0.0153
52wk Range
0.0100 - 0.0299
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
Lobe Sciences Provides Company Review of 2023
January 08, 2024
From
Lobe Sciences Ltd.
Via
Business Wire
Performance
YTD
+10.07%
+10.07%
1 Month
+4.08%
+4.08%
3 Month
-17.30%
-17.30%
6 Month
+9.29%
+9.29%
1 Year
-37.04%
-37.04%
More News
Read More
Lobe Sciences Provides Update on L-130 Clinical Program
December 07, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
December 05, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
March 01, 2023
Via
TheNewswire.com
Lobe Sciences, Ltd. Announces Amendment to the Acquisition of Altemia™ & Company
September 14, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
Via
Benzinga
This Biotech Is Entering The Clinical Stage With A Psilocin Analog Targeting Cluster Headaches
June 28, 2023
Via
Benzinga
Lobe Sciences Initiates Phase 1 Clinical Trial of L-130
June 27, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Mass-Scale Psilocin Clinical Supplies Are Ready For Upcoming Trials
October 14, 2022
Via
Benzinga
Lobe Sciences Appoints Baxter Phillips III, MBA as Chief Operating Officer
June 07, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Lobe Sciences Announces Commercial Distribution Agreement With Pentec Health for US Launch of Altemia™
May 17, 2023
From
Lobe Sciences Ltd.
Via
Business Wire
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
Via
Benzinga
Psyched Business: Lobe Buys Rare Disease Treatment, Plus Healing CREI And Heally Team Up
April 20, 2023
Via
Benzinga
Chronic Cluster Headaches No More: The Promise Of Lobe Sciences' At-Home Psychedelic Treatments Without The Trip!
February 28, 2023
Via
Benzinga
Chronic Cluster Headaches, Next Target For This Non-Hallucinogenic Psychedelic
January 27, 2023
Via
Benzinga
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry
January 26, 2023
Via
FinancialNewsMedia
Topics
Economy
Exposures
Supply Chain
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache
January 26, 2023
Via
FinancialNewsMedia
Exposures
Product Safety
Lobe Sciences Ltd (LOBEF) increases its portfolio with several new chemical entities (NCEs)
January 19, 2023
Via
AB Newswire
Topics
Intellectual Property
Exposures
Intellectual Property
Trippy Trading: Top Psychedelic Stocks For 2023
January 17, 2023
Via
TheNewswire.com
Topics
Cannabis
Exposures
Cannabis
Lobe Sciences Announces Incorporation of Australian Subsidiary
September 23, 2022
Via
Newsfile
Lobe Sciences Announces Closing of Private Placement
September 08, 2022
Via
Newsfile
Psychedelics Funding At Its Best: $1.5 M Destined To Psilocybin Clinical Trials In Australia
September 01, 2022
Via
Benzinga
Lobe Sciences and Cantheon Capital Enter into Exclusive Investment Agreement to Fund $1.5M USD Toward Clinical Trials in Australia
September 01, 2022
Via
Newsfile
Topics
Cannabis
Exposures
Cannabis
This Psychedelic Company Just Signed An Exclusive Deal For Psilocin Clinical Trials In Australia
August 10, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.